前列腺癌患者的雄激素剥夺疗法和功能:对RADICAL-PC队列的分析
Geethan Baskaran1, Jehonathan H Pinthus2, Sarah Karampatos3,4
1Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. Geethan.baskaran@phri.ca.
International urology and nephrology
|March 11, 2026
概括
前列腺癌患者的雄激素剥夺疗法 (ADT) 与以前没有ADT的患者相比,功能下降的速度较慢. 需要进一步的研究来理解ADT.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 前列腺癌 (PC) 管理通常涉及雄激素剥夺疗法 (ADT).
- 对ADT对功能的影响,这是患者健康的关键因素,需要进行彻底评估.
- 了解与ADT相关的功能变化对于长期PC患者护理至关重要.
研究的目的:
- 调查抗雄激素剥夺疗法 (ADT) 对被诊断为前列腺癌 (PC) 的患者功能的影响.
- 为了比较ADT暴露和ADT先前PC患者之间估计的淋巴球过率 (eGFR) 降低的速度.
主要方法:
- 在10个国家对未来的RADICAL-PC队列 (NCT03127631) 的分析.
- 使用从2年随访期间的肌素测量中获得的eGFR来量化功能.
- 使用线性混合效应回归用于ADT-eGFR关联和Cox回归用于住院期间损伤的统计模型.
主要成果:
- 总共有4742名患者被纳入分析.
- 与ADT暴露的患者相比,以前没有接受过ADT的患者的EGFR下降率显著更高 (-1.322毫升/分钟/1.73m2/年) (-0.706毫升/分钟/1.73m2/年).
- 在住院期间,ADT和损伤之间没有发现显著的关联 (HR1.37,p=0.135).
结论:
- 启动ADT与与前列腺癌患者的ADT-naive患者相比,eGFR的较小下降有关.
- 观察到的效果可能受到ADT介导的肌素生成减少的影响,需要进一步调查.
- 这些发现凸显了PC患者ADT和功能之间的复杂关系.
相关概念视频
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
437
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
437
01:28Chronic Kidney Disease III: Interprofessional Care
565
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
565
01:11Renal Failure: Dose Adjustments
556
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
556
01:28Kidney Transplant I: Introduction
637
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
637
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
290
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
290
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K